HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1,2-didecanoyl-3-phosphatidic acid (PA(10))

induces release of beta-glucuronidase from electropermeabilized neutrophils

Also Known As:

PA(10); 1,2-didecanoyl-3-sn-phosphatidic acid

Networked: 42 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Lipids: 114793
- Membrane Lipids: 1591
  - Phospholipids: 11903
    - Glycerophosphates: 118
      - Phosphatidic Acids: 358
        1,2-didecanoyl-3-phosphatidic acid: 42

Experts

1.	Ghossein, Ronald: 2 articles (01/2019 - 01/2015)
2.	Katabi, Nora: 2 articles (01/2019 - 01/2015)
3.	Hermann, Dirk M: 2 articles (01/2005 - 04/2004)
4.	Kilic, Ertugrul: 2 articles (01/2005 - 04/2004)
5.	Kilic, Ulkan: 2 articles (01/2005 - 04/2004)
6.	Hossmann, K A: 2 articles (10/2000 - 03/2000)
7.	Chen, Huangtao: 1 article (06/2022)
8.	Gong, Li: 1 article (06/2022)
9.	Heng, Lijun: 1 article (06/2022)
10.	Li, Qing: 1 article (06/2022)

Related Diseases

1.	Ischemia 08/01/2013 - "It is safe and effective to treat lower limb ischemia by combining adjunctive endovascular intervention with bolus of rt-PA (10 to 20 mg) given by a new infusion system. " 01/01/2020 - "Ischemia was induced in male Sprague Dawley rats by eMCAO, after which they were treated with 2-BFI (3 mg/kg) at 0.5 h in combination with rt-PA (10 mg/kg) at 6 or 8 h. " 04/01/2004 - "melatonin (4 + 4 mg/kg, after induction of ischemia and at reperfusion onset) administered either alone or in combination with the thrombolytic tissue-plasminogen activator (t-PA, 10 mg/kg), on cerebral laser Doppler flow (LDF) and ischemic injury were studied after 30 min of middle cerebral artery (MCA) thread occlusion in male C57BL/6 mice. " 10/01/2013 - "In our mouse model of cerebral ischemia, administration of rt-PA (10 mg/kg, i.v.) 6h after ischemia aggravated the post-ischemic degradation of ZO-1, claudin-5 and VE-cadherin, increased the hemorrhagic transformations (assessed by brain hemoglobin content and magnetic resonance imaging). "
2.	Infarction (Infarctions) 03/01/2000 - "Administration of rt-PA (10 mg/kg) 15 min after clot injection induced a progressive LDF restoration to approximately 115% of control values after 2 h, and brought about a significant reduction of the infarct volume (62.3 +/- 42.4 mm(3)). " 10/01/1992 - "Rt-PA 10 mg kg-1 reduced median infarct volume (in percent of the ipsilateral hemisphere volume) from 19.5 to 4.8; rt-PA 15 mg kg-1 to 2.0; rt-PA 20 mg kg-1 to 0.0, while rt-PA 10 mg kg-1 + aspirin resulted in a median infarct volume of 9.5%. "
3.	Myocardial Infarction 02/01/1993 - "Two hundred and seventy patients under 71 years of age with myocardial infarction less than 4 hours old, defined by clinical and electrocardiographic criteria, were included in this trial and followed up for 1 year: two groups of 89 and 92 patients were randomised to receive APSAC (30 mg i.v. over 5 minutes) or rt-PA (10 mg bolus + 5000 IU of heparin as a bolus, followed by 90 mg rt-PA over 3 hours) and compared with a control series of 89 consecutive patients treated with streptokinase (1.5 MU in 1 hour). " 11/01/1992 - "A hundred and eighty three patients with a primary myocardial infarction less than 4 hours old were included in a double blind trial versus placebo comparing an isolated plasminogen streptokinase activator complex (APSAC: 30 mu in 5 mn) and tissue type plasminogen activator (rt PA: 10 mg bolus followed by 90 mg in 130 mn). "
4.	Hypertension (High Blood Pressure) 05/01/2017 - "With the linear cubic spline model, when compared with inactive individuals, for those who met the guidelines recommended minimum level of moderate PA (10 metabolic equivalent of task h/wk), the risk of hypertension was reduced by 6% (relative risk, 0.94; 95% confidence interval, 0.92-0.97). " 11/01/1995 - "Patients whose hypertension is controlled by nifedipine-PA 10 or 20 mg bid can be successfully converted to nifedipine-GITS with most patients remaining normotensive on 30 mg daily." 11/01/1995 - "Patients with controlled hypertension (diastolic blood pressure less than 90 mmHg) on nifedipine-PA 10 mg (n = 74) or 20 mg (n = 99) bid were enrolled into an open label study consisting of six weeks of previous nifedipine-PA followed by six weeks of nifedipine-GITS therapy. " 01/01/2009 - "Coronary heart disease risk factors assessed were low levels of daily PA (<10,000stepsday(-1)), high-blood pressure (>95th percentile), overweight (>85th percentile) and/or obese (>95th percentile), presence of family history of heart disease, low cardio-respiratory fitness (poor estimated VO(2)max), and being a smoker. "
5.	Pulmonary Atresia (Pulmonary Valve Atresia) 01/01/2012 - "Among those having a two-ventricle repair, anatomic pulmonary atresia (APA) was a risk factor for early mortality (46.1%, 6 of 13) compared with those without pulmonary atresia (EA/no-PA; 10%, 1 of 10), P < .05. " 01/01/2013 - "The current study aimed to develop a reliable targeted array comparative genomic hybridization (aCGH) to detect microdeletions and microduplications in congenital conotruncal defects (CTDs), especially on 22q11.2 region, and for some other chromosomal aberrations, such as 5p15-5p, 7q11.23 and 4p16.3. Twenty-seven patients with CTDs, including 12 pulmonary atresia (PA), 10 double-outlet right ventricle (DORV), 3 transposition of great arteries (TGA), 1 tetralogy of Fallot (TOF) and one ventricular septal defect (VSD), were enrolled in this study and screened for pathogenic copy number variations (CNVs), using Agilent 8 x 15K targeted aCGH. "

Related Drugs and Biologics

1.	Streptokinase
2.	Anistreplase (APSAC)
3.	Tissue Plasminogen Activator (Alteplase)
4.	Heparin (Liquaemin)
5.	Plasminogen
6.	Nifedipine (Adalat)
7.	beta-cyclodextrin tetradecasulfate (CTDS)
8.	Carrageenan
9.	Claudin-5
10.	Enoxaparin (Lovenox)

Related Therapies and Procedures

1.	Therapeutics
2.	Lasers (Laser)
3.	Intraperitoneal Injections